Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion

Mervyn B. Forman, Christos J. Pitarys, Harry D. Vildibill, Thomas L. Lambert, David Ingram, Renu Virmani, John J. Murray

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Previous studies have demonstrated that intravenous administration of large doses of Fluosol, a perfluorochemical preparation, reduced infarct size 24 h after reperfusion, an effect that was associated with reduced neutrophil infiltration. The effect of a clinically tolerable dose of Fluosol on infarct size after a prolonged period of reperfusion and its mechanism of action on neutrophils remain unknown. Twenty-one anesthetized closed chest dogs were subjected to 90 min of proximal left anterior descending coronary artery occlusion and 72 h of reperfusion. An additional five dogs that did not undergo regional myocardial ischemia were utilized to explore the mechanism of action of Fluosol on neutrophil function. In the infarct study, animals were randomized to receive either intravenous Fluosol (n = 10) or an equivalent volume of Ringer's lactate solution (control; n = 11) at 15 ml/kg body weight during the last 30 min of occlusion and for the 1st 30 min of reperfusion. Fluosol significantly reduced infarct size when expressed as percent area at risk 72 h aller reperfusion (13.7 ± 2.7% vs. 38.3 ± 4.5%, respectively, p <0.001). This reduction was associated with significant improvement in regional wall motion (18.4 ± 2.3% vs. 5.5 ± 2%, p <0.001). Endocardial blood fiow in the ischemic bed was significantly higher 3 h after reperfusion in Fluosol-treated dogs (0.63 ± 0.08 vs. 0.34 ± 0.07 ml/min per g, p = 0.01). Reduced capillary plugging by neutrophils with relative preservation of endothelial cell structure was observed in Fluosol-treated animals. Infusion of Fluosol produced a marked transient decrease in peripheral neutrophil and platelet counts in both ischemic and nonischemic dogs and was associated with a significant reduction in total hemolytic complement levels. Studies of neutrophil function ex vivo revealed a reduction in chemotaxis and lysozyme degranulation after infusion of Fluosol. In vitro experiments showed that Fluosol produced a rapid and sustained activation of neutrophils determined by superoxide anion production. These data demonstrate that low dose intravenous Fluosol produces a sustained reduction in infarct size in the canine model. The beneficial effect may be in part due to the suppression of various neutrophil functions in the reperfused myocardium subsequent to peripheral activation by Fluosol. Such interventions may offer a novel therapy to enhance myocardial salvage by sequestration of circulating neutrophils during the critical early reperfusion period.

Original languageEnglish (US)
Pages (from-to)205-216
Number of pages12
JournalJournal of the American College of Cardiology
Volume19
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Reperfusion
Canidae
Neutrophils
Dogs
fluosol
Complement Hemolytic Activity Assay
Neutrophil Activation
Neutrophil Infiltration
Coronary Occlusion
Chemotaxis
Muramidase
Platelet Count
Superoxides
Intravenous Administration
Myocardial Ischemia
Coronary Vessels
Myocardium
Thorax
Endothelial Cells
Body Weight

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. / Forman, Mervyn B.; Pitarys, Christos J.; Vildibill, Harry D.; Lambert, Thomas L.; Ingram, David; Virmani, Renu; Murray, John J.

In: Journal of the American College of Cardiology, Vol. 19, No. 1, 1992, p. 205-216.

Research output: Contribution to journalArticle

Forman, Mervyn B. ; Pitarys, Christos J. ; Vildibill, Harry D. ; Lambert, Thomas L. ; Ingram, David ; Virmani, Renu ; Murray, John J. / Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. In: Journal of the American College of Cardiology. 1992 ; Vol. 19, No. 1. pp. 205-216.
@article{b6023b2f6e744277abce0517305f0b3a,
title = "Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion",
abstract = "Previous studies have demonstrated that intravenous administration of large doses of Fluosol, a perfluorochemical preparation, reduced infarct size 24 h after reperfusion, an effect that was associated with reduced neutrophil infiltration. The effect of a clinically tolerable dose of Fluosol on infarct size after a prolonged period of reperfusion and its mechanism of action on neutrophils remain unknown. Twenty-one anesthetized closed chest dogs were subjected to 90 min of proximal left anterior descending coronary artery occlusion and 72 h of reperfusion. An additional five dogs that did not undergo regional myocardial ischemia were utilized to explore the mechanism of action of Fluosol on neutrophil function. In the infarct study, animals were randomized to receive either intravenous Fluosol (n = 10) or an equivalent volume of Ringer's lactate solution (control; n = 11) at 15 ml/kg body weight during the last 30 min of occlusion and for the 1st 30 min of reperfusion. Fluosol significantly reduced infarct size when expressed as percent area at risk 72 h aller reperfusion (13.7 ± 2.7{\%} vs. 38.3 ± 4.5{\%}, respectively, p <0.001). This reduction was associated with significant improvement in regional wall motion (18.4 ± 2.3{\%} vs. 5.5 ± 2{\%}, p <0.001). Endocardial blood fiow in the ischemic bed was significantly higher 3 h after reperfusion in Fluosol-treated dogs (0.63 ± 0.08 vs. 0.34 ± 0.07 ml/min per g, p = 0.01). Reduced capillary plugging by neutrophils with relative preservation of endothelial cell structure was observed in Fluosol-treated animals. Infusion of Fluosol produced a marked transient decrease in peripheral neutrophil and platelet counts in both ischemic and nonischemic dogs and was associated with a significant reduction in total hemolytic complement levels. Studies of neutrophil function ex vivo revealed a reduction in chemotaxis and lysozyme degranulation after infusion of Fluosol. In vitro experiments showed that Fluosol produced a rapid and sustained activation of neutrophils determined by superoxide anion production. These data demonstrate that low dose intravenous Fluosol produces a sustained reduction in infarct size in the canine model. The beneficial effect may be in part due to the suppression of various neutrophil functions in the reperfused myocardium subsequent to peripheral activation by Fluosol. Such interventions may offer a novel therapy to enhance myocardial salvage by sequestration of circulating neutrophils during the critical early reperfusion period.",
author = "Forman, {Mervyn B.} and Pitarys, {Christos J.} and Vildibill, {Harry D.} and Lambert, {Thomas L.} and David Ingram and Renu Virmani and Murray, {John J.}",
year = "1992",
doi = "10.1016/0735-1097(92)90074-W",
language = "English (US)",
volume = "19",
pages = "205--216",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion

AU - Forman, Mervyn B.

AU - Pitarys, Christos J.

AU - Vildibill, Harry D.

AU - Lambert, Thomas L.

AU - Ingram, David

AU - Virmani, Renu

AU - Murray, John J.

PY - 1992

Y1 - 1992

N2 - Previous studies have demonstrated that intravenous administration of large doses of Fluosol, a perfluorochemical preparation, reduced infarct size 24 h after reperfusion, an effect that was associated with reduced neutrophil infiltration. The effect of a clinically tolerable dose of Fluosol on infarct size after a prolonged period of reperfusion and its mechanism of action on neutrophils remain unknown. Twenty-one anesthetized closed chest dogs were subjected to 90 min of proximal left anterior descending coronary artery occlusion and 72 h of reperfusion. An additional five dogs that did not undergo regional myocardial ischemia were utilized to explore the mechanism of action of Fluosol on neutrophil function. In the infarct study, animals were randomized to receive either intravenous Fluosol (n = 10) or an equivalent volume of Ringer's lactate solution (control; n = 11) at 15 ml/kg body weight during the last 30 min of occlusion and for the 1st 30 min of reperfusion. Fluosol significantly reduced infarct size when expressed as percent area at risk 72 h aller reperfusion (13.7 ± 2.7% vs. 38.3 ± 4.5%, respectively, p <0.001). This reduction was associated with significant improvement in regional wall motion (18.4 ± 2.3% vs. 5.5 ± 2%, p <0.001). Endocardial blood fiow in the ischemic bed was significantly higher 3 h after reperfusion in Fluosol-treated dogs (0.63 ± 0.08 vs. 0.34 ± 0.07 ml/min per g, p = 0.01). Reduced capillary plugging by neutrophils with relative preservation of endothelial cell structure was observed in Fluosol-treated animals. Infusion of Fluosol produced a marked transient decrease in peripheral neutrophil and platelet counts in both ischemic and nonischemic dogs and was associated with a significant reduction in total hemolytic complement levels. Studies of neutrophil function ex vivo revealed a reduction in chemotaxis and lysozyme degranulation after infusion of Fluosol. In vitro experiments showed that Fluosol produced a rapid and sustained activation of neutrophils determined by superoxide anion production. These data demonstrate that low dose intravenous Fluosol produces a sustained reduction in infarct size in the canine model. The beneficial effect may be in part due to the suppression of various neutrophil functions in the reperfused myocardium subsequent to peripheral activation by Fluosol. Such interventions may offer a novel therapy to enhance myocardial salvage by sequestration of circulating neutrophils during the critical early reperfusion period.

AB - Previous studies have demonstrated that intravenous administration of large doses of Fluosol, a perfluorochemical preparation, reduced infarct size 24 h after reperfusion, an effect that was associated with reduced neutrophil infiltration. The effect of a clinically tolerable dose of Fluosol on infarct size after a prolonged period of reperfusion and its mechanism of action on neutrophils remain unknown. Twenty-one anesthetized closed chest dogs were subjected to 90 min of proximal left anterior descending coronary artery occlusion and 72 h of reperfusion. An additional five dogs that did not undergo regional myocardial ischemia were utilized to explore the mechanism of action of Fluosol on neutrophil function. In the infarct study, animals were randomized to receive either intravenous Fluosol (n = 10) or an equivalent volume of Ringer's lactate solution (control; n = 11) at 15 ml/kg body weight during the last 30 min of occlusion and for the 1st 30 min of reperfusion. Fluosol significantly reduced infarct size when expressed as percent area at risk 72 h aller reperfusion (13.7 ± 2.7% vs. 38.3 ± 4.5%, respectively, p <0.001). This reduction was associated with significant improvement in regional wall motion (18.4 ± 2.3% vs. 5.5 ± 2%, p <0.001). Endocardial blood fiow in the ischemic bed was significantly higher 3 h after reperfusion in Fluosol-treated dogs (0.63 ± 0.08 vs. 0.34 ± 0.07 ml/min per g, p = 0.01). Reduced capillary plugging by neutrophils with relative preservation of endothelial cell structure was observed in Fluosol-treated animals. Infusion of Fluosol produced a marked transient decrease in peripheral neutrophil and platelet counts in both ischemic and nonischemic dogs and was associated with a significant reduction in total hemolytic complement levels. Studies of neutrophil function ex vivo revealed a reduction in chemotaxis and lysozyme degranulation after infusion of Fluosol. In vitro experiments showed that Fluosol produced a rapid and sustained activation of neutrophils determined by superoxide anion production. These data demonstrate that low dose intravenous Fluosol produces a sustained reduction in infarct size in the canine model. The beneficial effect may be in part due to the suppression of various neutrophil functions in the reperfused myocardium subsequent to peripheral activation by Fluosol. Such interventions may offer a novel therapy to enhance myocardial salvage by sequestration of circulating neutrophils during the critical early reperfusion period.

UR - http://www.scopus.com/inward/record.url?scp=0026536732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026536732&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(92)90074-W

DO - 10.1016/0735-1097(92)90074-W

M3 - Article

C2 - 1729335

AN - SCOPUS:0026536732

VL - 19

SP - 205

EP - 216

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 1

ER -